Whereas human clinical trials with autologous bone marrow-derived MSCs (BM-MSCs) demonstrated safety and reduced circulating levels of inflammatory marker C-reactive protein (CRP), beneficial effects on lung function in emphysema patients were limited [11,12]. This evidence concerns the gene CRP and pulmonary emphysema.